Posters

      Cilia of human MucilAir (TM) are less impacted by the exposure to the aerosol of a candidate modified risk tobacco product than to whole smoke from conventional cigarettes in vitro

      Frentzel, S.; Grandolfo, D.; Kuehn, D.; Majeed, S.; Leroy, P.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Mar 17, 2016
      Conference name
      Society of Toxicology (SOT) 2016
      Link to more information
      Link to more information
      Topic
      Summary

      Mucociliary clearance is an important defense mechanism that mediates removal of foreign particles and chemicals from the airways. Cilia beating thereby plays a key role that determines the rate of mucus clearance and thus constitutes a vital function of respiratory epithelia. Cigarette smoke has been reported to adversely impact cilia function in vitro and in vivo, by changing cilia beating frequency (CBF) or impairing ciliogenesis. To monitor CBF, semi-automated methods such as CiliaFA combine high-speed video recording with the ability to determine CBF. Using CiliaFA, we were able to confirm that the MucilAirTM CBF can be modulated in vitro by either 100 µM isoproterenol or a temperature shift to 4°C. Moreover, in vitro exposure of MucilAirTM with whole smoke from conventional cigarettes (3R4F at 0 mg/L, 0.15 mg/L and 0.25 mg/L nicotine) caused a decrease in the total surface area of the culture showing active cilia beating. Cilia on the epithelial cell surface that were detected to be still active after 3R4F exposure, showed variable beat frequencies, ranging from normal to decreased CBF. Compared to 3R4F cigarette smoke exposure, the effect of equivalent concentrations (based on nicotine) of a candidate modified risk tobacco product (MRTP: THS2.2) aerosol was much less pronounced, i.e. the total surface area of cilia beating as well as beating frequency was less impacted by THS2.2. Overall, this study clearly discriminated the effects of THS2.2 from the deleterious impact of 3R4F on cilia beating. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.